PhysioAssist has developed a unique expertise in bronchial mucus analysis and clearance. Their model of digital simulation allowed for a detailed analysis of the impact of vibrational signals on human mucus in the distant airways of the bronchi. The stagnation of mucus in these areas is often considered to be a root cause of pulmonary infections. Patients with obstructive pathologies have to clear their airways on a daily basis.
PhysioAssist’s lead product, Simeox™, delivers a simple solution to clear airways efficiently, particularly suited for COPD and Cystic Fibrosis patients. It is currently commercialized in France and some countries within Western Europe.
A session of treatment with Simeox™ typically lasts for 10 to 20 minutes and is supervised by a healthcare professional, and can be provided at home, to improve quality of life and patient compliance.
Venture Capital
Divested
Europe
Financing round - Series B
Medical Devices
2017
Status
Creation Date
Number of Employees
Investment Date
Fund Name